Aromatase inhibitors in the management of early breast cancer |
| |
Authors: | J.M. Nabholtz |
| |
Affiliation: | Breast Cancer Research Institute, La Prandie, 24290 Valojoulx, France |
| |
Abstract: | The adjuvant treatment of patients with endocrine-sensitive breast cancer has been dominated for several decades by the gold-standard tamoxifen. Promising results on the third-generation aromatase inhibitors (AIs), anastrozole, letrozole and exemestane, in advanced disease led to the development of these agents in the treatment of early breast cancer. Recent results consistently show the superiority of these agents over tamoxifen, and the therapeutic strategies of AIs in the adjuvant setting are still being discussed. Various approaches have been evaluated, including the following:- 1.
- upfront 5-year use of an AI instead of tamoxifen for newly diagnosed patients,
|
| |
Keywords: | Breast cancer Adjuvant treatment Aromatase inhibitors Tamoxifen |
本文献已被 ScienceDirect 等数据库收录! |
|